Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Abstract Cancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cell lung cancer. Programmed death receptor-1/programmed death receptor ligand-1 (PD-1/PD-L1) and cytotoxic T lymphocyte-as...

書誌詳細
出版年:	Journal of Hematology & Oncology
主要な著者:	Weishi Cheng, Kai Kang, Ailin Zhao, Yijun Wu
フォーマット:	論文
言語:	英語
出版事項:	BMC 2024-07-01
主題:	Lung cancer Immune checkpoint inhibitor Bispecific antibody Combination therapy Biomarker
オンライン･アクセス:	https://doi.org/10.1186/s13045-024-01581-2

類似資料

Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity
著者:: Yoichiro Narikawa, 等
出版事項: (2025-08-01)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
著者:: Tianye Li, 等
出版事項: (2023-07-01)

Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo
著者:: Zheng Wang, 等
出版事項: (2024-12-01)

Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies
著者:: Xiaodong Wang, 等
出版事項: (2025-10-01)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
著者:: Iris Koopmans, 等
出版事項: (2018-08-01)

Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade
著者:: Wang L, 等
出版事項: (2024-09-01)

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
著者:: Allan Relecom, 等
出版事項: (2021-02-01)

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
著者:: Adil Parvez, 等
出版事項: (2023-12-01)

Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy
著者:: Junjun Fu, 等
出版事項: (2023-03-01)

Complete Blood Count-Derived Biomarkers’ Association with Risk of PD-1 or PD-1/CTLA-4 Inhibitor-Induced Hypothyroidism in Patients with Solid Tumors
著者:: Ketevan Lomidze, 等
出版事項: (2025-06-01)

A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody
著者:: Qi Song, 等
出版事項: (2024-11-01)

Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison
著者:: Linyan Cheng, 等
出版事項: (2024-04-01)

Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1
著者:: Weimin Chen, 等
出版事項: (2021-01-01)

CTLA-4 and PD-1 combined blockade therapy for malignant melanoma brain metastases: mechanisms, challenges, and prospects
著者:: Jia-Wen Wang, 等
出版事項: (2025-07-01)

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
著者:: Xin Su, 等
出版事項: (2024-08-01)

Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade
著者:: Nina B. Curkovic, 等
出版事項: (2025-12-01)

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
著者:: Hao Zhang, 等
出版事項: (2023-03-01)

Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy
著者:: Irene Tang, 等
出版事項: (2023-05-01)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
著者:: Xuan Zhao, 等
出版事項: (2022-08-01)

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
著者:: Judith A. Seidel, 等
出版事項: (2018-03-01)

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
著者:: Ning Shi, 等
出版事項: (2022-11-01)

Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study
著者:: Yilin Wang, 等
出版事項: (2025-04-01)

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade
著者:: Przemysław Bielski, 等
出版事項: (2025-05-01)

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
著者:: Johannes Sam, 等
出版事項: (2020-11-01)

Emerging technology trends in regulatory approvals of cancer immunotherapy drugs by the FDA and EMA
著者:: Maryam Monajati, 等
出版事項: (2024-09-01)

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
著者:: Laura Rubio-Pérez, 等
出版事項: (2023-12-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
著者:: Jinhua Liu, 等
出版事項: (2021-09-01)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
著者:: Xianjing Chu, 等
出版事項: (2023-06-01)

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation
著者:: Oana Hangiu, 等
出版事項: (2025-01-01)

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
著者:: Kongju Wu, 等
出版事項: (2019-10-01)

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
著者:: Xinghua Pang, 等
出版事項: (2023-12-01)

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy
著者:: Xiaofan Su, 等
出版事項: (2022-06-01)

Emerging Trends in Immunotherapy for Cancer
著者:: Alok K. Mishra, 等
出版事項: (2022-09-01)

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
著者:: Arefeh Zabeti Touchaei, 等
出版事項: (2024-03-01)

Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1
著者:: Irene Cattaneo, 等
出版事項: (2024-02-01)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
著者:: Jingjing Duan, 等
出版事項: (2018-09-01)

Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer
著者:: Emily Wolf, 等
出版事項: (2025-01-01)

Blockade of CCR5+ T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody
著者:: Ming Yi, 等
出版事項: (2024-11-01)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
著者:: Jan-Michael Werner, 等
出版事項: (2019-02-01)

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade
著者:: Stefan Warmuth, 等
出版事項: (2021-01-01)